BridgeMD
Remimazolam versus Midazolam for sedation during upper GI endoscopy: a randomized controlled trial
EU CTIS ID: 2024-516432-94-00
What this study is testing
To evaluate the duration required for complete patient recovery following the administration of midazolam and remimazolam for procedural sedation during diagnostic upper GI endoscopies.
- Therapeutic use (Phase IV)
A plain-language read of the study's public EU CTIS listing. The study team confirms the details.
Who can take part
You may be able to join if
- Patients age ≥ 18 years.
- Scheduled for a diagnostic upper GI endoscopy with procedural sedation.
- Ability to provide written informed consent, and to understand the responsibilities of trial participation.
You likely can't join if
- Anticipated use of opioids, such as a therapeutic endoscopy or any other reason.
- ASA score of 4.
- Subject has a known history of unresolved drug or alcohol dependency that would limit ability to comprehend or follow instructions related to informed consent.
The study team makes the final eligibility decision.
Questions & answers
Do participants get paid in this trial?
This listing doesn't specify compensation. Many trials still reimburse travel or offer a stipend, so it's worth asking the study team when you connect.
Is it free to join, and do I need insurance?
Searching and applying through BridgeMD is free. In clinical trials the study-related treatment and visits are generally provided at no cost to you. You usually don't need insurance to take part - confirm specifics with the study team.
How long does this study last?
The listing doesn't state an exact length. The study team walks you through the schedule and number of visits before you decide to enroll.
Who can join this trial?
This study is enrolling all sexes, 65+ years, 18-64 years. The study team makes the final eligibility decision.
Explore other conditions
BridgeMD is an information and trial-matching tool - not medical advice, and not the study sponsor. Details come from EU CTIS; the study team decides eligibility.